Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 44-53 , January 2007

Management of Chronic Kidney Disease Mineral-Bone Disorder

  • Stephen Z. Fadem

      Affiliations

    • Baylor College of Medicine, Division of Nephrology, Houston, TX
    • Corresponding Author InformationAddress correspondence to Stephen Z. Fadem, MD, FACP, FASN, 6655 Travis, Suite 720, Houston, TX 77030.
    • ,
  • Sharon M. Moe

      Affiliations

    • Indiana University School of Medicine, Department of Medicine, Indianapolis, IN

References 

  1. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171–1178
  2. de Francisco AL. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther. 2004;26:1976–1993
  3. Dusso A, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: A mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol. 2004;89-90:507–511
  4. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–567
  5. White KE, Larsson TM, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frp-4, MEPE, and FGF23. Endocr Rev. 2006;(in press)
  6. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: Does it matter in nephrology?. Semin Dial. 2003;16:186–188
  7. Bell RR, Draper HH, Tzeng DY, et al. Physiological responses of human adults to foods containing phosphate additives. J Nutr. 1977;107:42–50
  8. Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant. 2002;17:1419–1425
  9. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026–1033
  10. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37:S54–S57
  11. K/DOQI NKF. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl):S1–S201
  12. Alfrey AC. Aluminum and renal disease. Contrib Nephrol. 1993;102:110–124
  13. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome (Possible aluminum intoxication). N Engl J Med. 1976;294:184–188
  14. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders (A theoretical, in vitro, and in vivo study). J Clin Invest. 1989;83:66–73
  15. Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17:544–550
  16. Hujairi NM, Afzali B, Goldsmith DJ. Cardiac calcification in renal patients: What we do and don’t know. Am J Kidney Dis. 2004;43:234–243
  17. McCullough PA, Sandberg KR, Dumler F, et al. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol. 2004;17:205–215
  18. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33:694–701
  19. Slatopolsky EA, Burke SK, Dillon MA The RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 1999;55:299–307
  20. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  21. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20:1653–1661
  22. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  23. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
  24. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42:96–107
  25. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant. 2004;19:1902–1906
  26. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65:191–202
  27. Damment SJ, Shen V. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol. 2005;63:127–137
  28. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21:2217–2224
  29. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005;64:428–437
  30. D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003;85(suppl):S73–S78
  31. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855–861
  32. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–1951
  33. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697–703
  34. McIntyre CW, Patel V, Taylor GS, et al. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant. 2002;17:1643–1648
  35. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol. 1998;9:859–868
  36. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43:558–565
  37. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int. 2006;70:345–350
  38. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716
  39. Gonzalez EA, Sachdeva A, Oliver DA, et al. Vitamin D insufficiency and deficiency in chronic kidney disease (A single center observational study). Am J Nephrol. 2004;24:503–510
  40. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637–1642
  41. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial. 2005;18:266–275
  42. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D and blood pressure in the Third Tational Health and Nutritional Examination Survey. Proceedings of the 13th Workshop on Vitamin D: 512006
  43. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17(suppl 10):10–19
  44. Martin KJ, Gonzalez EA, Gellens M, et al. 19-nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427–1432
  45. Frazao JM, Chesney RW, Coburn JW 1-alpha-D2 Study Group. Intermittent oral 1-alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant. 1998;13(suppl 3):68–72
  46. Frazao JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1-alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000;36:550–561
  47. Tan AU, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997;51:317–323
  48. Akiba T, Marumo F, Owada A, et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998;32:238–246
  49. Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1-alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis. 2001;37:532–543
  50. Yasuda M, Akiba T, Nihei H. Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. Am J Kidney Dis. 2003;41(suppl):S108–S111
  51. Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis. 1995;26:852–860
  52. Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis. 2002;40:1283–1288
  53. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483–1490
  54. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456
  55. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  56. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  57. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70:351–357
  58. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865
  59. Thadani R, Wolf Myles. Vitamin D in patients with kidney disease: Cautiously optomistic. Adv Chronic Kidney Dis. 2007;14:22–26
  60. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int. 1995;48:259–272
  61. Berl T, Berns AS, Hufer WE, et al. 1,25 dihydroxycholecalciferol effects in chronic dialysis: A double-blind controlled study. Ann Intern Med. 1978;88:774–780
  62. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43:877–890
  63. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–276
  64. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580
  65. Goodman WG. Calcium-sensing receptors. Semin Nephrol. 2004;24:17–24
  66. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000;58:436–445
  67. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575–583
  68. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248–254
  69. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  70. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003;23:369–379
  71. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20:2186–2193
  72. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800

PII: S1548-5595(06)00166-2

doi: 10.1053/j.ackd.2006.10.004

Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 44-53 , January 2007

Article Tools

* Image Usage & Resolution